Prognoza
Średnia cena docelowa analityków wynosi 71,25 € (+43,94%). Mediana wynosi 59,24 € (+19,68%).
| Kupuj |
7 |
| Trzymaj |
2 |
| Sprzedaj |
1 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Liquidia ends patent dispute with United Therapeutics and secures market access for Yutrepia
Liquidia has entered into a global settlement agreement with United Therapeutics, thereby ending all patent litigation. Supply of PAH patients with the dry‑powder formulation Yutrepia remains fully uninterrupted. Liquidia will not appeal and has removed the PH-ILD indication from the product information. » Więcej na finanzen.net
Liquidia reports strong YUTREPIA growth, pipeline expansion and positive profitability
Liquidia said at the Wells Fargo Healthcare Conference that YUTREPIA generated $170 million in revenue in Q2 2026 and that quarterly sales have increased by about $40 million in each of the past three quarters. About 75% of prescriptions are for treatment‑naive patients, and the company reported EBITDA of roughly $100 million, net income of about $80 million and an additional $60 million of cash flow in the quarter. Liquidia is expanding its commercial and clinical programs with 8–10 planned studies in the next 12 months, plans L606 as a follow‑on program, expects long‑term revenue above $1 billion, but faces an outstanding patent ruling. » Więcej na de.investing.com
Liquidia Corporation: Yutrepia launch outpaces expectations, litigation likely to be resolved
The Summers Value Fund named Liquidia Corporation a top contributor after the Yutrepia launch continued to exceed investor expectations and is expected to sustain momentum. The fund expects a near-term favorable resolution of litigation that could unlock further gains. Liquidia shares are up 141.61% over the past year (down 22.08% in the past month) and the company has a market capitalization of $6.24 billion. » Więcej na finance.yahoo.com
Greenhaven Road Capital posts Q2 gain, trims concentration and realized short-term gain on Liquidia
Greenhaven Road Capital reported an approximate 11% net return in Q2 2026 and said it will lower portfolio concentration, increase positions with near-term catalysts and take a more proactive approach to profit-taking. The firm emphasized continued focus on high-quality businesses and research that challenges consensus as several large holdings face near-term events. Greenhaven noted it sold a portion of its Liquidia position after a >30% pre-verdict rise, realizing a short-term gain, and will reassess the investment following the patent dispute outcome. » Więcej na finance.yahoo.com
Liquidia Technologies rises premarket ahead of Q2 results on YUTREPIA momentum
The stock of Liquidia Technologies rose 2.7% in premarket trading after the company announced its Q2 2026 results before the open and a management webcast at 8:30 a.m. ET. Analyst consensus expects about $165 million in revenue and $0.70 EPS, supported by a history of positive earnings surprises. Strong commercialization of YUTREPIA (over 4,500 prescriptions, about 3,750 treatment starts, conversion rate ≥85%) and recent price-target increases (including H.C. Wainwright $130, BTIG $109) are driving positive sentiment; the stock has gained about 105% since the end of March. » Więcej na de.investing.com
Dane finansowe
W ostatnim kwartale Liquidia osiągnęła przychody w wysokości 198,91 mln € i zysk netto w wysokości -208,64 mln €
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 198,91 mln | 329,54% |
| Zysk brutto | 185,86 mln | 326,26% |
| Zysk netto | -208,64 mln | 6830,31% |
| EBITDA | -232,17 mln | 7107,58% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 4,47 mld € |
Liczba akcji | 90,11 mln |
Maksimum/minimum z 52 tygodni | 85,31 € - 20,33 € |
| Dywidendy | Nie |
Beta | 0,54 |
C/Z (PE Ratio) | -52,84 |
PEG (PEG Ratio) | 0,03 |
C/WK (PB Ratio) | -191,58 |
C/S (PS Ratio) | 7,89 |
Profil spółki
Liquidia Corporation to firma biofarmaceutyczna, która opracowuje, wytwarza i komercjalizuje różne produkty odpowiadające na niezaspokojone potrzeby pacjentów w Stanach Zjednoczonych. Jej kandydaci na produkty obejmują YUTREPIA, wziewną formulację treprostynilu w postaci suchego proszku, przeznaczoną do leczenia tętniczego nadciśnienia płucnego. Firma dystrybuuje także generyczny roztwór treprostynilu do wstrzykiwań w Stanach Zjednoczonych. Liquidia Corporation została założona w 2004 roku i ma siedzibę główną w Morrisville w Północnej Karolinie.
| Nazwa | Liquidia |
| CEO | Roger A. Jeffs |
| Siedziba | Morrisville,
nc Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 26.07.2018 |
| Pracownicy | 216 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | LQDA |
Frankfurt | LT4.F |
Düsseldorf | LT4.DU |
München | LT4.MU |